Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892293 · ClinicalTrials.gov registry record · Phase 1
CT Antigen TCR-Engineered T Cells for Myeloma
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01892293 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 6 participants.
The verdict
NCT01892293, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
Interventions
- DRUG Treatment with NY-ESO-1c259-modified T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10-15 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01892293
The ClinicalTrials.gov registry entry for NCT01892293 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with NY-ESO-1c259-modified T cells is the first listed.
NCT01892293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01892293 about?
NCT01892293 is a clinical study titled "CT Antigen TCR-Engineered T Cells for Myeloma". This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
What is the current status of trial NCT01892293?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10-15. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT01892293?
The interventions under investigation include: Treatment with NY-ESO-1c259-modified T cells (DRUG).
Who is sponsoring clinical trial NCT01892293?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.